The hormone replacement therapy market is witnessing substantial growth due to the rising occurrence of hormonal and targeted conditions such as menopause and osteoporosis, coupled with the growing elderly population, which is fueling demand for HRT. Increased awareness about menopause management, interest in regenerative medicine—including anti-aging and reproductive therapies—a rise in drug approvals, new product launches, and the active involvement of key market players underscore the vibrant nature of the HRT market, which is expected to expand significantly between 2024 and 2030. LAS VEGAS , Sept.
26, 2024 /PRNewswire/ -- DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, individual leading hormone replacement therapy companies' market shares, challenges, hormone replacement therapy market drivers, barriers, trends, and key market hormone replacement therapy companies in the market. Key Takeaways from the Hormone Replacement Therapy Market Report As per DelveInsight estimates, North America is anticipated to dominate the global hormone replacement therapy market during the forecast period. In the indication segment of the hormone replacement therapy market, the menopause category had a significant revenue share in 2023.
Notable hormone replacement therapy companies such as Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc.
, F.Hoffman.
